BioAge Labs, Inc.
bioagelabs.comWhat Do They Do?
Develops therapeutic drug candidates for metabolic diseases using insights into human aging biology, with a focus on cardiometabolic diseases and eye conditions.
10-K for FY2025, filed Mar 24, 2026We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology…View ↗
We intend to advance BGE-102 in two therapeutic areas: cardiometabolic disease and ophthalmology.View ↗
Beyond NLRP3 inhibition, we are also developing novel apelin receptor APJ agonists for obesity, including programs targeting both oral and…View ↗
We are also advancing earlier stage platform-derived programs in collaboration with Eli Lilly and Company (Lilly), and have an ongoing…View ↗
How Do They Make Money?
The company has no products approved for sale and has not earned product-sales revenue. It receives collaboration payments for licenses, research and development work, milestone achievements and, potentially, royalties on future product sales.
10-K for FY2025, filed Mar 24, 2026Since our inception in 2015, we have devoted substantially all of our efforts to organizing and staffing our company, business planning…View ↗
Collaborative Arrangements – The Company has entered into collaboration agreements, which are within the scope of ASC 606, to discover…View ↗
Royalties – For arrangements that include sales-based royalties, including milestone payments based on a level of sales, which are the…View ↗
$9M
-
10-K for FY2025, filed Mar 24, 2026
$9M ↗
Who Are Their Customers?
Its customers are collaboration partners, including Lilly and Novartis, which work with BioAge on drug discovery and development programs.
10-K for FY2025, filed Mar 24, 2026We are also advancing earlier stage platform-derived programs in collaboration with Eli Lilly and Company (Lilly), and have an ongoing…View ↗
We are advancing several additional platform targets, currently in molecule discovery stage in collaboration with Lilly, which we believe…View ↗
Collaborative Arrangements – The Company has entered into collaboration agreements, which are within the scope of ASC 606, to discover…View ↗
Do Revenues Turn Into Profits?
No. It lost $80.6M in FY2025.
10-K for FY2025, filed Mar 24, 2026
−$92.8MView ↗
10-K for FY2025, filed Mar 24, 2026
−$80.6MView ↗
10-K for FY2025, filed Mar 24, 2026
−$82.3MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 5, 2026
−$26.1MView ↗
- ▲ +21% (Loss)
- vs −$21.6M in Q2 FY2025
-
Aug 5, 2026
Started dosing the first participant in its Phase 2 cardiovascular trial
The BGE-102 trial measures inflammatory and cardiometabolic biomarkers; topline data are anticipated in the second half of 2026.
Sources
8-K, filed Aug 5, 2026
First participant dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic…View ↗
Who Do They Compete With?
Competes with Ventyx Biosciences, NodThera, Roche, Merck, Novo Nordisk, AstraZeneca, Neumora, Ventus, Tenvie, Insilico, Brenig, Zydus, Structure Therapeutics, Bristol Myers Squibb, APIE Therapeutics, and Sanofi
10-K for FY2025, filed Mar 24, 2026Many of our current or potential competitors, either alone or with their collaboration partners, have significantly greater financial…View ↗
Loading...
